These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2643969)

  • 1. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study.
    Lind L; Wengle B; Wide L; Ljunghall S
    Am J Hypertens; 1989 Jan; 2(1):20-5. PubMed ID: 2643969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension in primary hyperparathyroidism--reduction of blood pressure by long-term treatment with vitamin D (alphacalcidol). A double-blind, placebo-controlled study.
    Lind L; Wengle B; Wide L; Sörensen OH; Ljunghall S
    Am J Hypertens; 1988 Oct; 1(4 Pt 1):397-402. PubMed ID: 3063290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance.
    Lind L; Lithell H; Skarfors E; Wide L; Ljunghall S
    Acta Med Scand; 1988; 223(3):211-7. PubMed ID: 3281411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study.
    Lind L; Wengle B; Ljunghall S
    Acta Med Scand; 1987; 222(5):423-7. PubMed ID: 3321926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of intracellular calcium and plasma renin by dietary calcium in men.
    Petrov V; Lijnen P
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1217-24. PubMed ID: 10619585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind randomized, crossover trial of calcium supplementation in essential hypertension.
    Zoccali C; Mallamaci F; Delfino D; Ciccarelli M; Parlongo S; Iellamo D; Moscato D; Maggiore Q
    J Hypertens; 1988 Jun; 6(6):451-5. PubMed ID: 3045202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism.
    Lind L; Wengle B; Sørensen OH; Wide L; Akerström G; Ljunghall S
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):250-6. PubMed ID: 2644746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (alphacalcidol).
    Lind L; Wengle B; Lithell H; Ljunghall S
    J Intern Med; 1992 Apr; 231(4):427-32. PubMed ID: 1588270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of 1,25-(OH)2-vitamin D are not altered by long-term supplementation with alphacalcidol (1-OH-vitamin D3). A double-blind, placebo-controlled study.
    Lind L; Wengle B; Sörensen OH; Ljunghall S
    Exp Clin Endocrinol; 1992; 99(3):151-3. PubMed ID: 1526265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nocturnal diastolic blood pressure decline is associated with higher 25-hydroxyvitamin D level and standing plasma renin activity in a hypertensive population.
    Zhang M; Xu X; Liu H; Li H; Zhang J; Gao M
    Clin Exp Hypertens; 2017; 39(8):685-690. PubMed ID: 28872358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive and renal effects of isradipine in essential hypertension: focus on renin system activity.
    Allikmets K; Parik T; Teesalu R
    Angiology; 1997 Nov; 48(11):977-83. PubMed ID: 9373050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial.
    Bislev LS; Langagergaard Rødbro L; Nørgaard Bech J; Bjerregaard Pedersen E; Rolighed L; Sikjaer T; Rejnmark L
    Clin Endocrinol (Oxf); 2018 Nov; 89(5):656-666. PubMed ID: 29733445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral calcium supplementation on intracellular calcium and plasma renin in men.
    Lijnen P; Petrov V
    J Endocrinol; 1995 Sep; 146(3):421-9. PubMed ID: 7595137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone.
    Opsahl JA; Halstenson CE; Abraham PA
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):828-33. PubMed ID: 2686710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis.
    Fiad TM; Cunningham SK; Hayes FJ; McKenna TJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):457-60. PubMed ID: 9024236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine beta-hydroxylase and plasma renin activity in patients with low-, normal-, and high-renin essential hypertension.
    Lawton WJ; Fitz A; Grant C; Witte DL
    Circulation; 1979 May; 59(5):1063-9. PubMed ID: 428086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone and calcium. A relationship in hypertension.
    Zachariah PK; Schwartz GL; Strong CG; Ritter SG
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):79S-82S. PubMed ID: 3415813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of an oral calcium supplement in the treatment of slight-to- moderate essential arterial hypertension].
    Oliván Martínez J; Pérez Cano R; Miranda García MJ; Montoya García MJ; Moruno García R; Cuenca López L; Garrido Peralta M
    An Med Interna; 1989 Apr; 6(4):192-6. PubMed ID: 2491521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin levels and spironolactone treatment in general practice: similar blood pressure lowering effect of spironolactone in low and normal renin patients.
    Sundsfjord JA; Odegaard AE
    Eur J Clin Invest; 1977 Oct; 7(5):389-92. PubMed ID: 411668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.